Undisclosed PPI Program
Oncology
Key Facts
About Perha Pharmaceuticals
Perha Pharmaceuticals is a private, preclinical-stage biotech leveraging a specialized platform to drug protein-protein interactions (PPIs) in oncology and inflammation. As a typical early-stage biotech, it is pre-revenue and likely funded by venture capital and grants, with its value residing in its proprietary technology and pipeline potential. The company's success hinges on validating its platform by advancing programs into clinical trials, navigating the significant scientific and development risks inherent in targeting PPIs.
View full company profileAbout Perha Pharmaceuticals
Perha Pharmaceuticals is a private, preclinical-stage biotech leveraging a specialized platform to drug protein-protein interactions (PPIs) in oncology and inflammation. As a typical early-stage biotech, it is pre-revenue and likely funded by venture capital and grants, with its value residing in its proprietary technology and pipeline potential. The company's success hinges on validating its platform by advancing programs into clinical trials, navigating the significant scientific and development risks inherent in targeting PPIs.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |